About VirX | VirX Nasal Spray

Xtraordinary working of VirX

Your Nose is the entry gate for viruses & contaminants. Use of VirX NONS^TM delivers Nitric Oxide to the Nasal cavity which creates a hostile microenvironment in the nose where airborne viruses can’t survive. VirX allows for intranasal delivery of a topical, non-systemic, small amount of Nitric Oxide that is lethal to microbes but safe to humans.

Inhibits Entry

Physically it forms a protective layer and chemically low pH inactivates the viruses

Physical and Chemical Barrier:

Physical: Protective layer of Hydroxy propyl methyl cellulose
Chemical: Low pH of solution

ACE-2 blocking: Nitric Oxide in VirX binds to ACE2 receptor blocking Spike Protein fusion to nasal epithelial cells.

Direct Antiviral Effect

VirX alters host proteins required for viral multiplication and inhibits the growth of viruses.

Reduces Infectivity & Transmissibility

VirX brings conformation changes to spike protein and reduces its affinity to bind with the host receptor, thereby reducing the infectivity as well as its transmissibility.

Why to use VirX ?

Kills 99.9% of the viruses within 2 minutes

Scientifically proven effective in human clinical trials

Patented device delivers freshly formed Nitric Oxide

Effective on virus variants & microbes

8 hours of protection against SARS-CoV-2

Suitable for people aged over 12 years

VirX Nasal Spray prevents viruses from raising and spreading to the lungs by providing a physical and chemical barrier. It reduces viral load, even with only 2 nasal sprays a day.

Safe

The compounds used in the liquid are all used extensively in the food.

Effective

It reduces viral load 16 times higher than saline nasal spray and ensures a lasting protection.

Natural

Nitric Oxide in VirX Nasal are same as the body forms, also it is found primarily in green leafy vegetables.

Scientific Data

VirX against Respiratory Viruses

VirX Nitric Oxide Nasal Spray activity against wild SARS-CoV-2 variant of concern and other respiratory viruses:

Reference: Based on the result of Indian Phase 3 Clinical Trial - Data on file and standard supportive care was in accordance with latest guidelines issued by Ministry of Health and Family Welfare; Government of India.

Significantly faster negative RT-PCR conversion seen as early as 4 days

Reference: Indian Phase 3 Clinical Trial- Standard supportive care was in accordance with latest guidelines issued by Ministry of Health and Family Welfare; Government of India.